NCT04009668 2024-10-30
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
University of Michigan
Phase 2 Completed
Clinical Trials
12 trialsNCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT05073315 2024-02-09
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Amgen
Phase 3 Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT02163759 2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3 Completed
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT02499783 2019-01-04
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Phase 3 Completed
NCT02196701 2018-03-19
CLEAR
AbbVie
Phase 3 Completed
NCT02437253 2017-09-15
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
NCT00932113 2017-08-31
MOA
Tufts Medical Center
Phase 4 Completed
NCT01078571 2011-10-28
DALI
Abbott
Completed